What's Happening?
Symeres, a Netherlands-based contract research, development, and manufacturing organization (CRDMO), has expanded its spray drying capabilities at its Cranbury, New Jersey site. This expansion aims to support the formulation development of poorly soluble
and development-challenged small-molecule drug candidates. The enhanced capabilities will aid in bioavailability enhancement strategies, including amorphous solid dispersions and solubility optimization. This investment strengthens Symeres' integrated CMC offering, allowing for a seamless transition from early formulation screening to clinical-ready material, thereby reducing tech-transfer risks and accelerating development timelines.
Why It's Important?
The expansion of spray drying capabilities at Symeres' New Jersey site is a significant development for the pharmaceutical industry, particularly in the U.S. It addresses the growing need for advanced formulation techniques to improve the bioavailability of complex drug candidates. This capability is crucial for the development of modern small-molecule drugs, which often face solubility challenges. By enhancing its formulation capabilities, Symeres can better support pharmaceutical companies in bringing innovative therapies to market more efficiently. This development also underscores the importance of technological advancements in drug formulation and manufacturing.
